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Methicillin-resistant Staphylococcus aureus (MRSA) emerged as one of the
most important causes of hospital-acquired bloodstream infections (BSIs), especially
the multidrug resistant clones. The aim of the present study was to compare prevalence
and resistance patterns of MRSA bacteremia in the major tertiary-care academic and
referral center in Serbia before and after implementing an active antimicrobial
resistance (AMR) surveillance. Laboratory-based before-after study was conducted
during a two-year period (January 2012 to December 2013) in Clinical Centre of
Serbia. Isolation and identiﬁcation of bacterial strains were done following standard
microbiological procedures. During the AMR surveillance, nearly twice more blood-
stream samples were collected compared to the year without surveillance (1,528 vs.
855). In total, 43 isolates of MRSA were identiﬁed. MRSA was signiﬁcantly more
prevalent during the AMR surveillance compared to the previous year [14 (66.7%) to
29 (76.3%); P= 0.046]. During the AMR surveillance, MRSA more frequently
originated from medical departments compared to intensive care unit, surgical
department, and internal medicine (P= 0.027) indicating increasing MRSA infections
in patients with less severe clinical condition and no apparent risk factors. Higher
prevalence of MRSA and its lower susceptibility to erythromycin were revealed by
implementation of active AMR surveillance, which may reﬂect more thoughtful
collection of bloodstream samples from patients with suspected BSI.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most
important pathogens causing various infections in hospitals and community. Since
its ﬁrst detection in 1961, MRSA still imposes a priority in prevention and
management of hospital-acquired infections (HAIs), due to health and ﬁnancial
burden it delivers, especially in countries with limited resources. According to the
last ECDC technical report, MRSA accounted for the 44% of all HAIs and 12% of
all bacteremia in the EU states, Iceland, and Norway, while causing 22%
attributable extra deaths and 41% of in-hospital extra days [1]. Considering the
ﬁnancial burden, median attributable hospital charge for MRSA bacteremia in the
USA amounts to US$ 6,916 [2], while in Europe MRSA bloodstream infections
(BSIs) account for EUR 380 million extra costs annually [1].
Although moderate declining of hospital-acquired MRSA (HA-MRSA)
bacteremia was recently observed in a few European countries, the United States
and Australia [3–5], this pathogen is the most common single multidrug resistant
(MDR) cause of HAIs in Europe, the United States, Asia, and Brazil [6–9]. The
European/EEA population-mean of invasive HA-MRSA infections in 2013 was
18.0% [10]; however, these percentages vary greatly within a continent, from 0 in
Iceland up to 64.5% in Romania, indicating major differences in epidemiology of
MRSA bacteremia, while data from the non-EU states of the Balkan region remain
underrepresented.
Active surveillance is the ﬁrst and the vital step in the battle against MRSA
since it depicts the real extent of pathogen distribution and its antimicrobial
resistance (AMR) in a particular medical setting. The importance of well-
organized programs for infection surveillance and control was stressed out even
in 60s and 70s by the Center for Disease Control (CDC) [11]. By now most of the
countries have implemented some kind of infection control program and current
decrease in MRSA bacteremia in most of them was mainly attributed to the
interventions or action plans to prevent these infections [12, 13]. However, it is
hard to distinguish what is the contribution of the active surveillance per se and its
impact on the clinical susceptibility data.
Serbia established national committee for infection control in 2003, how-
ever, has not implemented neither general/MRSA-speciﬁc infection control
programs nor the national AMR action plan so far due to consistently high
MRSA rates. According to the last national point prevalence study of HAIs
conducted in 2010, 51% of all S. aureus infections were caused by MRSA strains
[14]. In 2013, Serbia has joined the CAESAR (Central Asian and Eastern
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European Surveillance of Antimicrobial Resistance) network, which is the
network of national AMR surveillance systems in all countries of the region that
are not part of the EARS-Net (European AMR Surveillance Network) coordinated
by ECDC, with the purpose to report AMR data on eight invasive bacteria of
public health and clinical importance, among which, S. aureus [15].
Pursuant to this, the aim of the present study was to compare prevalence and
resistance patterns of MRSA bacteremia before and after the implementation of
active microbiological surveillance in the setting with no national actions plans
and interventions regarding MRSA-related infection control.
Materials and Methods
National AMR surveillance network
The national AMR surveillance in Serbia, as a part of CAESAR network,
has started in January 2013. Detailed methods of data collection and quality
control are presented in CAESAR annual report of AMR [15]. In brief, it
comprises 14 patient-care laboratories that serve secondary and tertiary care
hospitals and covers nine out of 24 regions in Serbia, which represents more
than 40% of the entire population. The representative AMR results, based on
routine samples of blood and cerebrospinal ﬂuid, were collected by labs and
forwarded to the Reference Laboratory. Collected data comprised patients’
background information (an isolate record form) and antimicrobial susceptibility
test results of invasive isolates of S. aureus, Enterococcus faecalis, Enterococcus
faecium, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae,
Pseudomonas aeruginosa, and Acinetobacter spp. Data were submitted to the
reference laboratory either as a paper record form or electronically (by an e-mail).
Reference laboratory used WHONET 5.6 for data collection and analysis.
Study design and setting
A laboratory-based before-after study was conducted in a tertiary-care center
(Clinical Centre of Serbia – CCS) in Belgrade, the capital of Serbia, during a two-
year period (January 2012 to December 2013) in order to compare occurrence of
bacteremia caused byMRSA and other bacteria of public health importance before
and after the initiation of national AMR surveillance, as well as to compare
susceptibility patterns of MRSA strains with respect to AMR surveillance
implementation. Prior to beginning of the AMR surveillance, the clinicians were
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trained and encouraged to take blood samples from all patients presenting with
signs or symptoms of BSI, i.e., fever (>38 °C), chills or hypotension, as
recommended by Centers for Disease Control and Prevention/National Healthcare
Safety Network (CDC/NHSN) [16].
The CCS is the largest tertiary healthcare and academic institution in Serbia
comprising 28 departments and 3,500 beds. It serves the entire population of
Serbia, and performs nearly 6 million laboratory services annually.
Data collection
Data for the surveillance year (January 1 to December 31, 2013) were
collected from the standardized isolate record forms, which comprised microbio-
logical data and patient’s demographic information and were prospectively
collected by the afﬁliated patient-care microbiological laboratories of CCS
(Emergency Centre, Clinic for Infectious and Tropic Diseases and Polyclinic)
and forwarded to the principal laboratory (Polyclinic). Data on patients’ char-
acteristics were age, sex, and the department at the onset of bacteremia (surgery
department – SD; intensive care unit – ICU, internal medicine or other medical
departments). For the purpose of this study, we extracted surveillance data of
antimicrobial susceptibility test results of S. aureus isolates obtained from blood
cultures of adult patients hospitalized in various departments of the CCS. Only
primary blood culture per patient was analyzed and the ﬁrst invasive isolate per
culture was reported. Collected data was gathered and checked for consistency
with protocol agreed.
For the year previous to surveillance (January 1 to December 31, 2012),
susceptibility data of MRSA strains was collected retrospectively from the
laboratory protocols, which comprised microbiological data and patients’
demographic data. For the purpose of better comparability, only the same
laboratories which used to provide samples to the principal laboratory in both
years and cover the same clinical wards were included in the analysis. Suscepti-
bility data from 2012 that was not obtained using the same laboratory standards
and/or not in compliance with EARS-Net recommendations were excluded from
the analysis.
Microbiological assessment
In all laboratories, isolation and identiﬁcation of bacterial strains were done
following standard microbiological procedures. Antimicrobial susceptibility was
estimated by using Kirby–Bauer disc diffusion and using Vitek2 Automated
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System (bioMérieux, Marcy-I’Etoile, France). The spectrum of antimicrobial
drugs reported is in accordance with EARS-Net. Zone diameter was measured
and interpreted according to the Clinical and Laboratory Standards Institute
(CLSI) guidelines [17]. Strains which showed intermediate susceptibility (I) and
resistance (R) to the speciﬁc antibiotic were considered resistant (R). Methicillin
resistance of S. aureus was determined by using Kirby–Bauer disc diffusion
method with 30 μg cefoxitin disc (Becton Dickinson, Sparks, USA). A zone size of
≥22 mm was considered sensitive (S) and ≤21 mm was considered resistant (R).
Minimum inhibitory concentrations were determined by E-test and results were
interpreted according to CLSI clinical breakpoints.
Statistical analysis
Descriptive statistics was used to express the frequency of bacterial isolates
and their susceptibility patterns. Numbers and percentages were used for categor-
ical and ordinal data. Chi-square test or Fisher exact test was applied for two-group
comparison of categorical data. All statistical tests were two-sided and were
performed at the 5% signiﬁcance level. Statistical analysis was performed by
using the IBM SPSS Statistics version 20.0 software (IBM Corp., Armonk,
NY, USA).
Results
Flowchart of the process of blood cultures gathering during the two
consequent years, before and during the ﬁrst year of national AMR surveillance,
is presented numerically in Figure 1. During the active surveillance, approximately
one and a half times more samples were collected, starting from the blood culture
bottles obtained from patients with suspected BSI and consequently to the primary
isolates with positive microbial growth. In both years, Gram-positive bacteria were
predominantly cultured (57% and 68%), followed by Gram-negative bacteria
(23% and 21%) and fungi (20% and 11%). However, the all three types of
causative agents were signiﬁcantly more prevalent during the AMR surveillance
compared to the previous year (P< 0.001) (Figure 2).
The distributions of the invasive bacteria of public health importance that are
subjected to annual reporting to CAESAR, as well as the percent of changes
during the two years of follow up (before and during the AMR surveillance), are
shown in Table I. Acinetobacter spp. and K. pneumoniae were the most prevalent
bacteria in both years, followed by E. faecium and S. aureus. P. aeruginosa,
S. pneumoniae, and E. coli were less frequently isolated than the above-mentioned
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bacteria, before and during the AMR surveillance. When comparing those two
years, signiﬁcant change in frequency was observed for four out of eight bacteria.
While frequency of Acinetobacter spp. and E. faecalis decreased from 51% to
41.9% and from 6.1% to 3.3%, respectively, K. pneumoniae and S. aureus
2013
Blood culture bottles 22.160 14.590
Primary isolates 855 (23.4%) 1,528 (27.6%)
Primary isolates with 
positive microbial 
growth
662 (77.4%) 1,268 (83%)
2012
Blood culture sets 3,648 5,540
Primary isolates of 
bacteria of clinical and 
public-health importance
371 (48.4%) 418 (33.0%)























Peroid of pathogen isolation
Gram-positive bacteria Gram-negative bacteria Fungi
P < 0.001
Figure 2. Types of causative agents of bloodstream infections before (2012) and during (2013) the
AMR surveillance
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signiﬁcantly increased during the AMR surveillance. Interestingly, increment of
S. aureus has occurred due to the increase of methicillin-resistant strains
[14 (66.7%) to 29 (76.3%); P= 0.046].
In a year prior to AMR surveillance, MRSA strains were predominantly
isolated from males and middle-aged and elderly inpatients, while during the
surveillance year MRSA strains were more frequently isolated from females and
middle-age patients (Table II). However, medical wards from which MRSA





(n = 29) P-value
Gender, n (%)
Male 8 (57.1) 12 (41.4) 0.331
Female 6 (42.9) 17 (58.6)
Age, n (%)
20–65 6 (42.9) 16 (55.2) 0.640
>65 6 (42.9) 11 (37.9)
Missing 2 (14.3) 2 (6.9)
Hospital ward, n (%)
ICU 7 (50.0) 8 (27.6) 0.027
Surgery 2 (14.3) 7 (24.1)
Internal department 3 (21.4) 3 (10.3)
Medical departments 2 (14.3) 11 (37.9)
Note: MRSA, methicillin-resistant Staphylococcus aureus; ICU, intensive care unit. Bold value is
statistically signiﬁcant (P< 0.05).







Acinetobacter spp. 192 (51.8) 175 (41.9) −9.9 <0.001
Klebsiella pneumoniae 63 (16.9) 111 (26.6) 9.7 0.001
Enterococcus faecium 43 (11.6) 40 (9.6) −2.0 0.363
Enterococcus faecalis 23 (6.1) 14 (3.3) −2.8 0.046
Staphylococcus aureus 21 (5.7) 38 (9.1) 3.4 0.026
Methicillin-resistant
S. aureus
14 (66.7) 29 (76.3) 9.6 0.046
Methicillin-sensitive
S. aureus
7 (33.3) 9 (23.7) −9.6 1.000
Pseudomonas aeruginosa 11 (2.9) 19 (4.5) 1.6 0.529
Streptococcus pneumoniae 10 (2.7) 1 (0.2) 2.5 0.062
Escherichia coli 8 (2.2) 20 (4.8) 2.6 0.352
Total 371 (100.0) 418 (100.0)
Note: Bold values are statistically signiﬁcant (P< 0.05).
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isolates originated signiﬁcantly changed in favor of medical departments (37%),
while isolation of MRSA in the ICU and internal department reduced by double
(P= 0.027).
Results of antimicrobial susceptibility testing and change in fraction of
resistant strains of MRSA isolates before and during the AMR surveillance are
shown in Table III. In both years, MRSA was highly resistant to gentamicin and
ciproﬂoxacin. Moreover, before the AMR surveillance all MRSA isolates were
resistant to rifampicin as well, and moderately resistant to clindamycin and
erythromycin, while completely susceptible to sulfamethoxazole-trimethoprim
(SMX-TMP). This pattern had changed in terms that during the AMR surveillance
implementation resistance to rifampicin signiﬁcantly decreased (100%–48.3%;
P= 0.001) while resistance to erythromycin increased (25%–62.1%; P= 0.043).
Importantly, in the year prior to AMR surveillance, only one MRSA strain
resistant to vancomycin and linezolid was isolated in the entire CCS, while in
AMR surveillance year all MRSA isolates were susceptible to those two last-line
antibiotics.









(%) P-valuean n (%) S n (%) R n n (%) S n (%) R
Aminoglycosides
Gentamicin 14 2 (14.3) 12 (85.7) 18 0 (0.0) 18 (100.0) 14.3 0.183
Glycopeptides
Vancomycin 12 11 (91.7) 1 (8.3) 29 29 (100.0) 0 (0.0) −8.3 0.293
Fluoroquinolones




14 0 (0.0) 14 (100.0) 29 15 (51.7) 14 (48.3) −51.7 0.001
Lincosamides
Clindamycin 14 9 (64.3) 5 (35.7) 28 10 (35.7) 18 (64.3) 28.6 0.107
Macrolides
Erythromycin 12 9 (75.0) 3 (25.0) 29 11 (37.9) 18 (62.1) 37.1 0.043
Oxazolidinones
Linezolid 14 13 (92.2) 1 (7.1) 27 27 (100.0) 0 (0.0) −7.1 0.341
Folate pathway inhibitors
SMX-TMP 14 14 (100.0) 0 (0.0) 25 21 (84.0) 4 (16.0) 16.0 0.277
Note: MRSA, methicillin-resistant Staphylococcus aureus; SMX-TMP, sulfamethoxazole-trimethoprim;
S, susceptible; R, resistant. Bold values are statistically signiﬁcant (P< 0.05).
aFisher exact test.
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Discussion
Over the course of antibiotic era, MRSA emerged as one of the most
important causes of nosocomial infections, especially the MDR clones, mainly due
to adverse outcomes and limited therapeutic options. Glycopeptides and recently
developed antibiotic linezolid are currently the last line antimicrobials, which
remain effective against HA-MRSA. Constant and accurate monitoring of its
prevalence and resistance patterns is, therefore, a necessity.
The main ﬁnding of the present surveillance study is substantially higher
prevalence of S. aureus isolated during the active AMR surveillance period
compared to previous year without surveillance, which more importantly, was
attributable to the increase of methicillin-resistant strains. This 10% increase (from
66.7% to 76.3%) is worrisome given the already high rates of MRSA infections in
CCS, which are therewithal, higher than the overall MRSA rates in Serbia in 2013
(42%) as well as in other four countries of the Region, which have submitted their
AMR data to the CAESAR (The former Yugoslav Republic of Macedonia, 41%;
Belarus, 35%; Turkey, 26%; and Switzerland, 5%) [15]. Of note is that of the listed
countries only Turkey and The former Yugoslav Republic of Macedonia have the
National AMR action plan developed.
Although surveillance data more objectively represents current situation
regarding MRSA infection in CCS, its generalizability to the entire country and
comparability to other countries are doubtful since the CCS is a tertiary care
hospital indebted for the most severe cases and that, consequently, majority of
MRSA originated from ICU and SD. Even though the pre-surveillance depart-
ment-distribution of MRSA in our study (50% ICU and 14% SD) is similar to the
results reported in Romanian teaching hospital and Macedonian Clinical Centre
[18, 19], these rates almost equalized during the surveillance year (27.6% ICU and
24.1% SD) while the medical departments featured predominantly (37.9%). It is
hard to ﬁnd the solid grounds that underpin such a difference within a single center
as well as to answer whether the surveillance play an important role. Presumably,
more heedful requesting of blood samples from inpatients with less severe clinical
condition in medical departments contributed to the increased MRSA rates
obtained from these wards. This is also in a line with recent reports on MRSA
infections emerging among patients with no evident risk factors [20]. Frequent
transfer of inpatients between ICU and SD may have contributed to the similar
MRSA rates in these wards. It is also shown that ICU and SD are the wards, which
most commonly use antibiotics for prophylactic purposes in Vojvodina region in
Serbia [21].
Regarding the AMR, we found high resistance to gentamicin, ciproﬂoxacin,
and clindamycin in both years, prior and during the active surveillance. These rates
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are more than twice higher than reported to CAESAR for the entire country
but similar to single clinical centers in neighboring countries, Romania and
Macedonia [18, 19]. Only rifampicin and erythromycin signiﬁcantly changed in
our study, ﬁrst lowered and second increased during the AMR surveillance.
Irrational use of antibiotics is one of the reasons for such a high prevalence of
MRSA and its AMR rates since Serbia is one of the southern and eastern European
countries with the highest rates of total antimicrobial consumption while second in
utilization of 1st generation cephalosporins, macrolides, and tetracycline [22].
Clonal and patients healthcare workers (HCWs) dissemination of MRSA is
another likely reason for the non-lowering MRSA rates after surveillance initia-
tion. Recent cross-sectional studies of MRSA carriage in CCS showed high
MRSA nasal and throat carriage rates, 11.8% in patients, and 7.6% in HCWs, and
predominance of CC5-MRSA-SCCmecI MRSA lineage in emergency and medi-
cal departments [23, 24]. Moreover, it was recently shown that genetic lineages
characteristic for community-acquired MRSA (CA-MRSA) (SCCmec types IV
and V) are more frequent than HA-MRSA lineages (SCCmec types I, II, and III) in
both hospitalized and healthy patients in Pomoravlje region in Serbia, indicating
transfer and adaptation of CA-MRSA strains to hospital environment and acquir-
ing additional resistance due to inadequate hygiene measures and selective
pressure of antibiotics [25]. Molecular typing surveillances are usually single-
center-based due to considerable ﬁnancial and human resources they require.
However, as demonstrated by few countries, including molecular typing data in
on-going AMR surveillance can delineate new molecular sequence types and
allow better understanding of molecular epidemiology of MRSA [26, 27].
While nationally and internationally conducted surveys depict global spread
and burden of the infection, locally derived ones are crucial in updating clinicians
and guiding them toward the most adequate empirical therapy [28, 29]. One of the
advantages of well-organized surveillance is larger number of collected samples,
which doubtlessly highlight which pathogen, when isolated, is the biggest threat
[30]. Signiﬁcant increase in collected blood-culture bottles and detection of
MRSA after initiation of national surveillance in our study are direct effects of
more systematic data collection and reporting in laboratories during the active
surveillance. However, laboratories were not provided with the data regarding the
origin of the BSIs, which is important for understanding the epidemiology of
MRSA bacteremia.
To the best of our knowledge, this is the ﬁrst study to delineate the
prevalence and resistance patterns of bloodstream MRSA isolates in the entire
CCS with respect to initiation of the active AMR surveillance. This kind of
pathogen monitoring is crucial especially in countries like Serbia, where due to
limited resources all efforts are curative-oriented and little or no investment is
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allocated to preventative measures [31]. In such a setting, it has multiple
contributions by substantially inﬂuencing the image of AMR extent which can
increase awareness among clinicians and public health authorities and more
importantly it can allow wiser and more justiﬁed allocation of resources to
prevent HAIs.
The main limitation of the study refers to the uncontrolled before-after
design and involves the time trend bias which can lead to overestimation of the
inﬂuence of the implemented survey. It implies uncertainty whether changes
occurred due to surveillance itself or are the consequence of secular trends or
sudden changes [32]. Prevalence and department distribution of MRSA isolates
are likely inﬂuenced by more systematic data collection during the AMR
surveillance, on the other hand, AMR rates and patterns are the effect of more
complex interactions between microbial genetics and antibiotic selective
pressure, which is required to be assessed as well. However, results of an
active, standardized survey of MRSA AMR are more representative of current
situation regarding MRSA frequency and resistance than unsystematic data
collection.
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